Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- CLINICAL THERAPEUTICS41(8) · pp.1499 · 2019
- 피인용
- Web of Science 17Scopus 17
- FWCI (Scopus)
- 0.92
- JCR IF
- JCR 2018 2.935
- ISSN
- 0149-2918
저자
- Chang, Hyuk-Jae제1저자Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Song, ShinjeongDivision of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
- Chang, Sung-A.Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
- Kim, Hyung-KwanDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
- Jung, Hae-OkCardiovascular Center, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
- 최정현Division of Cardiology, Pusan National University Hospital, Pusan, South Korea
- Lee, Jae SeungDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- Kim, Kye-HunThe Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Gwangju, South Korea
- Jeong, Jin-OkDepartment of Internal Medicine, Cardiovascular Center, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, South Korea
- Lee, Ju HeeDepartment of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, South Korea
- Kim, Duk-Kyung교신저자Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
초록
Purpose: Udenafil is an oral phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. In a multicenter, placebo-controlled, randomized Phase Ha study, the reduction of pulmonary vascular resistance index was greater with a 50-mg baseline dose of udenafil than with the 100-mg dose, the cardiac index did not decrease at most points, and the safety was excellent, suggesting that 50-mg udenafil could be used in a Phase ITO trial. Methods: In this 16-week, double-blind, placebo controlled study, 63 patients with pulmonary arterial hypertension were randomized to receive 50-mg udenafil or a placebo BID. The primary efficacy end point was the 6-min walking distance. The secondary efficacy end points were the Borg dyspnea score and time to clinical worsening. Patients who completed the 16-week study could participate in a long-term extension study. Findings: : In terms of the difference between the baseline and 16-week 6-min walking distance in both groups, the mean placebo-corrected treatment effect was 25 (58) m (P = 0.0873). Among the patients with a history of endothelin receptor antagonist therapy, the treatment effect at week 16 between the udenafil and placebo groups was 34 (60) m (P = 0.0460). However, there were no significant differences in the Borg dyspnea score and time to clinical worsening between groups. The safety profile and adverse effects of udenafil were similar to those of typical phosphodiesterase-5 inhibitors seen in previous studies. (C) 2019 Published by Elsevier Inc.
키워드
clinical trialpulmonary arterial hypertensionudenafil6-min walking distanceERECTILE DYSFUNCTIONTHERAPYAMBRISENTANMULTICENTERTADALAFILPRESSURE
식별자
- Scopus EID
- 2-s2.0-85067123521
- WoS UID
- 000487768700011



로그인
연구물 목록으로